Management of Opioid Overdose
Immediately administer naloxone at the lowest effective dose (0.4 mg intramuscularly or 2-4 mg intranasally) to restore normal respiratory rate, provide rescue breathing or positive pressure ventilation as needed, and observe the patient in a healthcare setting until risk of recurrent toxicity is low 1, 2.
Immediate Response Algorithm
Step 1: Assess and Support Airway/Breathing
- Check for respiratory depression (slow or absent breathing) and decreased consciousness
- If not breathing normally, provide rescue breaths or positive pressure ventilation immediately
- Do NOT wait to determine if pulse is present—respiratory support takes priority 1
Step 2: Administer Naloxone
- Initial dose: 0.4 mg intramuscularly OR 2-4 mg intranasally 2
- Use the lowest dose needed to restore normal respiratory rate (not full consciousness) 2
- Higher-concentration intranasal naloxone (2 mg/mL) has similar efficacy to intramuscular administration 3
- Repeat small doses every 2-3 minutes if respiratory depression persists 1
Critical caveat: Naloxone's duration of action (30-90 minutes) is often shorter than the opioid's respiratory depressive effect, particularly with long-acting formulations or fentanyl 1. This creates risk for re-sedation.
Step 3: Manage Complications
- Opioid withdrawal: Naloxone precipitates withdrawal symptoms (anxiety, agitation, pain, nausea). This is expected and not life-threatening 1
- Pulmonary edema: Sudden-onset pulmonary edema can occur but responds readily to positive pressure ventilation 1
- Polysubstance use: Naloxone only reverses opioid effects; consider other substances contributing to altered mental status 4
Post-Resuscitation Management
Mandatory Observation Period
All patients must be observed in a healthcare setting until:
- Level of consciousness normalizes
- Vital signs stabilize
- Risk of recurrent opioid toxicity is low 1
Duration varies by opioid type:
- Fentanyl, morphine, heroin: Abbreviated observation may be adequate 1
- Long-acting or sustained-release opioids: Require prolonged observation (potentially 24+ hours) 1
Managing Recurrent Toxicity
If respiratory depression recurs:
- Administer repeated small naloxone doses OR
- Start continuous naloxone infusion 1
Pitfall to avoid: Discharging patients too early. The narrow treatment window with high-potency synthetic opioids like fentanyl means rapid re-sedation can occur 4.
Harm Reduction and Prevention
Naloxone Distribution
- All individuals with opioid use disorder should have access to take-home naloxone 2
- Community-wide naloxone distribution reduces opioid overdose deaths by 25-46% 2
- Train patients, families, and close contacts in overdose recognition and naloxone administration 1
Transition to Treatment
Critical: After acute overdose management, initiate medications for opioid use disorder (MOUD):
- Methadone or buprenorphine reduce all-cause mortality (adjusted HR 0.52; 95% CI 0.42-0.63) 2
- Only 25.1% of people with OUD receive these life-saving medications 2
- Offer MOUD before discharge from the emergency department
Evidence Strength Considerations
The 2023 American Heart Association guideline 1 provides the most authoritative and recent framework, supported by the 2026 JAMA review 2 showing clear mortality benefits of naloxone and subsequent MOUD. The evidence consistently demonstrates that naloxone remains effective against fentanyl and fentanyl analogs—the concern is not efficacy but rather the rapidity of overdose onset and narrow treatment window 4.
Key gap: Limited evidence exists for polysubstance overdoses where non-opioid substances contribute to toxicity, for which naloxone is ineffective 4, 5.